Syntach

Syntach AB, based in Lund, Sweden, is developing an innovative cardiac support system for patients with heart failure. The company's primary product, the Syntach Cardiac Support System (Syntach CS), is a minimally invasive device designed to enhance the natural movement of the heart and restore its pumping function. Unlike traditional technologies, the Syntach CS does not require open-heart surgery and is powered by an implanted battery, eliminating the need for a driveline through the skin. This approach aims to avoid many negative side effects associated with current assist devices.

The Syntach CS works by supporting and enhancing the natural movement of the atrioventricular plane in the heart, making each heartbeat more effective. It specifically targets the motion of the mitral valve plane during the cardiac cycle, which accounts for 60% of left ventricular stroke volume. The technology is based on recent research and insights into the importance of mitral valve plane displacement in cardiac function.

In addition to the cardiac support system, Syntach is also developing mitral valve intervention systems. The company collaborates with several academic research centers, including the Cardiac MR Group at the Department for Clinical Sciences and Clinical Physiology at Lund University.